What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. The average price target for ACADIA Pharmaceuticals has increased by 18.1% from the previous average price target of $30.00 to $35.43. The analysts' ratings are generally bullish.
November 06, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are generally bullish on ACADIA Pharmaceuticals. The average price target has increased by 18.1% to $35.43 over the past 3 months.
The increase in the average price target indicates that analysts are expecting the stock price to rise. This is generally a positive signal for the stock. The bullish ratings from the analysts also suggest a positive outlook for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100